NovaBay Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Justin Hall, CEO and General Counsel, will present a company overview and hold investor meetings at the 8th Annual Dawson James Small Cap Growth Conference being held Thursday, October 12, 2023 at the Wyndham Grand Harborside Hotel in Jupiter, Fla.
“We are excited to showcase the innovative products in our eyecare, skincare, and wound care business segments at this upcoming conference,” said Mr. Hall. “I’ll be presenting our future strategies to address the large market opportunities for the Avenova®, DERMAdoctor® and PhaseOne® brands.”
Investors interested in arranging a meeting with NovaBay management should contact Jody Cain at LHA Investor Relations. The NovaBay corporate presentation can be access from the Presentation page of the Investor Relations section of the Company’s website.
About NovaBay Pharmaceuticals, Inc.:
NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare, skincare and wound care products. NovaBay’s leading product Avenova® Antimicrobial Lid & Lash Solution is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is also available directly to consumers through online distribution channels such as Amazon. DERMAdoctor® offers more than 30 dermatologist-developed skincare products through the DERMAdoctor website, well-known traditional and digital beauty retailers, and international distributors. NovaBay also manufactures and sells effective, yet gentle and non-irritating wound care products. The PhaseOne® brand is distributed through commercial partners in the U.S. for professional use only, and the NeutroPhase® brand is distributed in China by China Pioneer Pharma Holdings, Limited. More information about NovaBay is available here.
NovaBay Pharmaceuticals Forward-Looking Statements
]Except for historical information herein, matters set forth in this press release may be forward looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of NovaBay Pharmaceuticals, Inc. This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our business strategies, current partnerships, marketing efforts, and any future revenue that may result from such partnerships and related marketing initiatives, as well as generally the Company’s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the size of the potential market for our products, the possibility that the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, and revenues will not be sufficient to meet the Company’s cash needs. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings and Registration Statement on Form S-1 filing with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Socialize and Stay Informed on NovaBay’s Progress
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Visit NovaBay’s Website
Avenova Purchasing Information
For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email [email protected]
Avenova.com
DERMAdoctor Purchasing Information
For DERMAdoctor purchasing information:
Please call 877-337-6237 or email [email protected]
DERMAdoctor.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20231002622088/en/
NovaBay Contact
Justin Hall
Chief Executive Officer and General Counsel
510-899-8800
[email protected]
Investor Contact
LHA Investor Relations
Jody Cain
310-691-7100
[email protected]
KEYWORDS: United States North America California Florida
INDUSTRY KEYWORDS: Research Other Health General Health Family Pharmaceutical Optical Consumer Science Biotechnology Women Medical Supplies Health Other Science
MEDIA: